When does Spiriva (tiotropium) lose exclusivity or go generic?
“Spiriva” is the brand name for tiotropium, an inhaled medicine. Tiotropium products have had multiple versions over time (for example, HandiHaler and Respimat), and the timing for generics depends on which specific Spiriva product you mean and what kind of protection is still in force (for example, patent protection vs. other forms of exclusivity).
To determine the exact “go generic” date, you need the specific drug label (Spiriva HandiHaler vs. Spiriva Respimat) and strength/dosage, since those can have different patent expiry timelines.
Is there already a generic Spiriva?
Generics and “authorized” alternatives can enter before the last brand patent expires, depending on the filing strategy and what is still protected for that particular product form. That means “generic Spiriva” may already be available for one formulation even if another formulation is still under protection.
If you tell me whether you mean Spiriva HandiHaler or Spiriva Respimat (and the dose), I can narrow the timing to the relevant expiry window.
Where can I check the exact patent expiry for my Spiriva version?
DrugPatentWatch.com tracks patent-related timelines for specific drug products and is a good way to verify the last relevant patent expiry for the formulation you’re asking about. You can look up Spiriva there and match the result to the product form you use.
Source: DrugPatentWatch.com – Spiriva (tiotropium) patent info
What details change the “generic date” the most?
The generic timing is most sensitive to:
- Which Spiriva product (HandiHaler vs. Respimat)
- Strength and dose (sometimes different protection)
- Whether you’re asking about “first generic approval,” “full loss of exclusivity,” or “last patent expiry”
Quick check: what do you mean by “Spiriva”?
Reply with the exact product name on your box (for example, “Spiriva HandiHaler 18 mcg” or “Spiriva Respimat 2.5 mcg”) and your country (US, UK, Canada, etc.). Then I can give the most relevant generic/expiry timing for that specific version.
Sources cited:
1. https://www.drugpatentwatch.com/